Abstract 999P
Background
Both donafenib and anti-PD-1 antibodies are indicated for uHCC, HAIC significantly improved treatment response over TACE in patients (pts) with large uHCC in a phase III trial. Considering the different mechanisms, this study aimed to investigate the safety and efficacy of donafenib combined with HAIC and sintilimab in pts with uHCC.
Methods
This is a prospective, single-arm phase II study. Pts with histologically diagnosed uHCC, no previous systemic treatment, Child-Pugh A5-B7, ECOG performance status (PS) of 0 or 1 were eligible for inclusion. Enrolled pts received donafenib (200 mg, bid), sintilimab (200 mg, q3w) and HAIC (oxaliplatin 85 mg/m2 2h, leucovorin 400 mg/m2 2h, fluorouracil bolus 400 mg/m2 in the first 10 minutes, and fluorouracil infusion 1200 mg/m2 for 23 hours, q3w) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR).
Results
From Dec 2021 to Apr 2023, 30 pts were enrolled: BCLC stage A/B/C: 4/10/16; Child-Pugh class A/B: 29/1; ECOG PS 0/1: 29/1. The median tumor size was 7.9 cm, 46.7% pts presented macro vascular invasion, 10.0% had extrahepatic metastasis. As of May 6, 2023, the median follow-up time was 102 days, the median number of HAIC was 3 times (range, 1-8). Based on mRECIST, the ORR was 82.1% (95% CI, 63.1% - 93.9%) with 4 (14.3%) complete responses (CR) and 19 (67.8%) partial responses (PR). The disease control rate (DCR) was 96.4% (95% CI, 81.7% - 99.9%). Of 28 pts evaluable for response, the conversion success rate was 64.3% (18/28), 13 of them received hepatectomy, 5 cases (38.5%) achieved complete pathological response and 6 cases (46.2%) achieved major pathological response. The median time to response (TTR) was 2.1 months. The median progression-free survival (PFS) was 10.2 months (95% CI, NR). The most common treatment-emergent adverse events (TEAEs) were thrombocytopenia, anemia and neutropenia. Grade 3-4 TEAEs occurred in 33.3% of pts. No grade 5 TEAEs were observed.
Conclusions
Combination treatment with donafenib and HAIC plus sintilimab showed promising clinical benefits and acceptable toxic effects in pts with uHCC. The enrollment and follow-up are continuing.
Clinical trial identification
NCT05166772.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18